Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers.
Khalid El BairiMariam AmraniSaid AfqirPublished in: Cancer medicine (2018)
The high mortality associated with oncological diseases is mostly due to tumors in advanced stages, and their management is a major challenge in modern oncology. Angiogenesis is a defined hallmark of cancer and predisposes to metastatic invasion and dissemination and is therefore an important druggable target for cancer drug discovery. Recently, because of drug resistance and poor prognosis, new anticancer drugs from natural sources targeting tumor vessels have attracted more attention and have been used in several randomized and controlled clinical trials as therapeutic options. Here, we outline and discuss potential natural compounds as salvage treatment for advanced cancers from recent and ongoing clinical trials and real-world studies. We also discuss predictive biomarkers for patients' selection to optimize the use of these potential anticancer drugs.
Keyphrases
- poor prognosis
- clinical trial
- drug discovery
- papillary thyroid
- end stage renal disease
- long non coding rna
- phase ii
- squamous cell
- double blind
- open label
- childhood cancer
- phase iii
- small cell lung cancer
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- placebo controlled
- palliative care
- risk factors
- patient reported outcomes
- prostate cancer
- working memory
- type diabetes
- randomized controlled trial
- cell migration
- drinking water
- cancer therapy
- drug delivery
- wound healing
- drug induced
- cardiovascular disease
- combination therapy